{"denoms":[{"counts":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"38"},{"groupId":"BG003","value":"13"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"116"}],"units":"Participants"}],"groups":[{"description":"Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.","id":"BG000","title":"MEDI3617 SINGLE AGENT TOTAL"},{"description":"Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.","id":"BG001","title":"MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL"},{"description":"Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.","id":"BG002","title":"MEDI3617 + BEVACIZUMAB Q2W TOTAL"},{"description":"Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.","id":"BG003","title":"MEDI3617 + PACLITAXEL TOTAL"},{"description":"Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.","id":"BG004","title":"MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL"},{"description":"Total of all reporting groups","id":"BG005","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.4","value":"61.4"},{"groupId":"BG001","spread":"11.9","value":"57.4"},{"groupId":"BG002","spread":"11.2","value":"57.7"},{"groupId":"BG003","spread":"12.7","value":"60.4"},{"groupId":"BG004","spread":"12.3","value":"56.7"},{"groupId":"BG005","spread":"11.9","value":"59.2"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"18"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"65"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"51"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Safety population included all participants who receive any treatment with MEDI3617."}